WO2015126808A3 - Hbv assay - Google Patents

Hbv assay Download PDF

Info

Publication number
WO2015126808A3
WO2015126808A3 PCT/US2015/016110 US2015016110W WO2015126808A3 WO 2015126808 A3 WO2015126808 A3 WO 2015126808A3 US 2015016110 W US2015016110 W US 2015016110W WO 2015126808 A3 WO2015126808 A3 WO 2015126808A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
transporter
inhibitors
hbv assay
nctp
Prior art date
Application number
PCT/US2015/016110
Other languages
French (fr)
Other versions
WO2015126808A2 (en
Inventor
John J. Baldwin
Original Assignee
Baldwin John J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baldwin John J filed Critical Baldwin John J
Publication of WO2015126808A2 publication Critical patent/WO2015126808A2/en
Publication of WO2015126808A3 publication Critical patent/WO2015126808A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

This invention relates to the discovery that members of the pyrrolotriazinyl class of IGF-1R kinase inhibitors also are inhibitors of the NCTP transporter and block taurocholic acid entry into hepatocytes. An IGF-1R kinase inhibitor such as described in U.S.P. 7,534,792, especially BMS-754807, blocks the NTCP transporter and is therefore useful in preventing Hepatitis B disease, cirrhosis, and hepatic cellular cancer. This preferred compound is (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide.
PCT/US2015/016110 2014-02-18 2015-02-17 Hbv assay WO2015126808A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461966188P 2014-02-18 2014-02-18
US61/966,188 2014-02-18

Publications (2)

Publication Number Publication Date
WO2015126808A2 WO2015126808A2 (en) 2015-08-27
WO2015126808A3 true WO2015126808A3 (en) 2015-10-22

Family

ID=53879223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/016110 WO2015126808A2 (en) 2014-02-18 2015-02-17 Hbv assay

Country Status (1)

Country Link
WO (1) WO2015126808A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054820A2 (en) * 2005-11-08 2007-05-18 Novartis Vaccines And Diagnostics Srl Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant
US20110124623A1 (en) * 2006-07-07 2011-05-26 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054820A2 (en) * 2005-11-08 2007-05-18 Novartis Vaccines And Diagnostics Srl Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant
US20110124623A1 (en) * 2006-07-07 2011-05-26 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SENKO TSUKUDA ET AL.: "NTCP Transporter as Novel Target for Anti-Hepatitis B Virus Agents.", CLIN RES INFECT DIS, vol. 1, no. 1, 16 February 2014 (2014-02-16), pages 1004 *
ZHONGGI DONG ET AL.: "Structure-Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP)''.", MOL. PHARMACEUTICS, vol. 10, no. 3, 2013, pages 1008 - 1019 *

Also Published As

Publication number Publication date
WO2015126808A2 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
EP3759237A4 (en) Ultra-sensitive detection of circulating tumor dna through genome-wide integration
EP3752491A4 (en) Heterocyclic compounds as kinase inhibitors
WO2015021457A3 (en) Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression
EP3797109A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2020003458A (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyrid in-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof.
EA201791066A1 (en) ASK1 INHIBITOR SOLID FORMS
DE602005015519D1 (en) Process for increasing the foamability of spray-dried powders
EP3828186A3 (en) Pyrimidinones as factor xia inhibitors
IL259163A (en) 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
MX2013011537A (en) Protein kinase inhibitors.
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
EP3483158A4 (en) Heterocyclic compound serving as fgfr4 inhibitor
EP3902787A4 (en) Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
WO2016063294A3 (en) Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
PE20170936A1 (en) NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE
EP3266774A4 (en) Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof
EP3750880A4 (en) Pyrazine-2(1h)-ketone compound acting as fgfr inhibitor
EP3255046A4 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
MX2015013365A (en) Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors.
IL273396A (en) 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors
EP3394039A4 (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
MX2018000959A (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof.
SG10201806450SA (en) PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15752597

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15752597

Country of ref document: EP

Kind code of ref document: A2